Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Artia Global Partners LP

Q1 2024 · 13F-HR

Artia Global Partners LPholdings as filed

Filed 2024-05-15 · accession 0001937964-24-000004

$497.5M
Reported value
49
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
532457958ELI LILLY & CO$89.5M18.0%115,000PUTSOLE
670100205NVONOVO-NORDISK A S$88.8M17.9%691,743CommonSOLE
532457108LLYELI LILLY & CO$72.0M14.5%92,593CommonSOLE
58933Y105MRKMERCK & CO INC$50.0M10.1%379,200CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$35.6M7.15%433,580CommonSOLE
00287Y109ABBVABBVIE INC$16.5M3.32%90,821CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$14.5M2.92%210,096CommonSOLE
04016X101ARGXARGENX SE$13.5M2.71%34,238CommonSOLE
046353108AZNNASTRAZENECA PLC$12.9M2.60%190,752CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$12.1M2.43%28,900CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$7.0M1.41%87,848CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$6.6M1.33%724,685CommonSOLE
23282W605CYTKCYTOKINETICS INC$6.3M1.26%89,525CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$6.2M1.25%45,000CommonSOLE
254604101IRONDISC MEDICINE INC$5.4M1.09%87,040CommonSOLE
92243G108PCVXVAXCYTE INC$5.2M1.05%76,255CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$4.1M0.82%61,590CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$4.0M0.81%85,765CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$3.6M0.72%124,440CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$3.4M0.68%119,488CommonSOLE
457669307INSMINSMED INC$3.2M0.64%118,236CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$2.7M0.53%53,930CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$2.4M0.48%15,894CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$2.3M0.46%52,492CommonSOLE
N5749R1002GHMERUS N V$2.3M0.45%50,171CommonSOLE
925050106VRNAVERONA PHARMA PLC$2.1M0.42%130,790CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$2.0M0.41%51,714CommonSOLE
159864107CRLCHARLES RIV LABS INTL INC$1.9M0.38%6,905CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$1.8M0.36%47,949CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$1.8M0.35%40,924CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$1.7M0.35%40,000CommonSOLE
04335A105ARVNARVINAS INC$1.7M0.33%40,000CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$1.5M0.30%100,000CommonSOLE
589492107MREOMEREO BIOPHARMA GROUP PLC$1.4M0.28%421,359CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$1.3M0.26%54,285CommonSOLE
75382E109RAPT THERAPEUTICS INC$1.2M0.25%137,308CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$1.1M0.23%52,476CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$1.1M0.21%51,500CommonSOLE
03589W102ANNXANNEXON INC$1.1M0.21%147,485CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$1.0M0.21%24,298CommonSOLE
556099109MGNXMACROGENICS INC$942,1830.19%64,007CommonSOLE
50127T109KURAKURA ONCOLOGY INC$842,0660.17%39,478CommonSOLE
45258J102IMVTIMMUNOVANT INC$691,3370.14%21,397CommonSOLE
09077A106BMEABIOMEA FUSION INC$530,0070.11%35,452CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$441,6620.09%58,190CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$415,7810.08%1,557CommonSOLE
28202V907EFFECTOR THERAPEUTICS INC$359,7500.07%25,000CALLSOLE
73730P108PSTXUSDPOSEIDA THERAPEUTICS INC$274,3460.06%86,002CommonSOLE
39868T1052JQGRITSTONE BIO INC$244,5870.05%95,170CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.